Published in

Taylor and Francis Group, Leukemia & Lymphoma, p. 1-4

DOI: 10.3109/10428194.2015.1091927

Links

Tools

Export citation

Search in Google Scholar

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

Journal article published in 2015 by Annette E. Hay ORCID, Alli Murugesan, Ashley M. DiPasquale, Tom Kouroukis, Irwindeep Sandhu, Vishal Kukreti, Nizar J. Bahlis, Johan Lategan, Donna E. Reece, John F. Lyons, Joana Sederias, Hao Xu, Jean Powers, Lesley K. Seymour, Tony Reiman
Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO